BHAT, ABHIJIT SURESH,BRADSHAW, CURT WILLIAM,LAURENT, OLIVER ALEXANDRE,LEE, ALICE,PRESTON, RICHARD RYAN,TUMELTY, DAVID,WOOD, LAUREN DIANE,YU, WEI HONG
申请号：
PE0000522013
公开号：
PE06432013A1
申请日:
2011.07.11
申请国别(地区):
PE
年份:
2013
代理人:
摘要：
Refers to a multifunctional conjugated Antibody (Mac), which comprises: (i) an Antibody or Antigen selected portion of the same entity cetiximab, rituximab, infliximab, adalimumab, natalizumab, omalizumab, ranibizumab and palivizumab, which comprises at least a portion of a region Kappa Constant light chain (CLK), comprising at least the remains 1 to 106 SEC ID no 15SEC sec id ID no 45, 46 or 47 sec id no no (ii) a Link comprising the Formula X - y - Z, where z is a group that is covalently attached to the Antibody and a connection chain is Biologically compatible linear or branched X is a Connected Group covalently bound to at least one Other efec Tor which is a Protein or a peptide binding Sequence comprising the ANG2 SEC ID no. 26,27,29 among others. In addition to such a Pharmaceutical Composition and a preparation method of the conjugate. The conjugated Antibody provides the benefit of bifunctional Therapy in the treatment of cancer.SE REFIERE A UN CONJUGADO DEL ANTICUERPO MULTIFUNCIONAL (MAC) QUE COMPRENDE: (i) UN ANTICUERPO, O PORCION DE ANTIGENO DEL MISMO SELECCIONADO ENTE RITUXIMAB, CETIXIMAB, INFLIXIMAB, ADALIMUMAB, NATALIZUMAB, OMALIZUMAB, RANIBIZUMAB Y PALIVIZUMAB, QUE COMPRENDE AL MENOS UN FRAGMENTO DE UNA REGION KAPPA CONSTANTE DE CADENA LIGERA (CLk), QUE COMPRENDE AL MENOS LOS RESTOS 1 A 106 DE LA SEC ID N° 15, SEC ID N° 45, SEC ID N° 46 O SEC ID N° 47 (ii) UN ENGARCE QUE COMPRENDE LA FORMULA X-Y-Z, DONDE Z ES UN GRUPO QUE ESTA CONECTADO COVALENTEMENTE AL ANTICUERPO Y ES UNA CADENA DE CONEXION BIOLOGICAMENTE COMPATIBLE LINEAL O RAMIFICADA X ES UN GRUPO CONECTADO COVALENTEMENTE AL MENOS UN RESTO EFECTOR EL CUAL ES UNA PROTEINA O UN PEPTIDO DE UNION A ANG2 QUE COMPRENDE LA SECUENCIA SEC ID N° 27,28, 29 ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION DEL CONJUGADO. DICHO CONJUGADO DE ANTICUERPO PROPORCIONA EL BENEFICIO DE LA TERAPIA BIFUNCIONAL EN EL TRATAMIENTO DE CANCER.
